Buprenorphine-Naloxone for Opioid Use Disorder: Reduction in Mortality and Increased Remission.

ABSTRACT:

Introduction

As fentanyl has become more readily available, opioid-related morbidity and mortality in the United States has increased dramatically. Preliminary studies suggest that high-affinity, partial mu-opioid receptor agonists such as the combination product buprenorphine-naloxone may reduce mortality from overdose and promote remission. With the escalating prevalence of opioid use disorder (OUD), it is essential to evaluate the effectiveness of opioid agonists like buprenorphine-naloxone. This study examines mortality and remission rates for OUD patients prescribed buprenorphine-naloxone to determine the efficacy of this treatment toward these outcomes.

Methods

We carried out a retrospective analysis using the US Collaborative Network database in TriNetX, examining de-

SUBMITTER: Paul KK 

PROVIDER: S-EPMC11610725 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature